SLx-4090

DRUG4 trials

Sponsors

Response Pharmaceuticals, University of Texas Southwestern Medical Center

Conditions

HyperlipidemiaHypertriglyceridemiaType 1 HyperlipoproteinemiaType 2 Diabetes

Phase 2

Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

CompletedNCT00562575

Response PharmaceuticalsHypertriglyceridemia

Start: 2007-05-31End: 2008-02-29Updated: 2023-11-18

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

CompletedNCT00810979

Response PharmaceuticalsHyperlipidemia

Start: 2009-01-31End: 2009-09-30Updated: 2023-11-18

A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

CompletedNCT00871936

Response PharmaceuticalsType 2 Diabetes

Start: 2009-04-30End: 2009-10-31Updated: 2023-11-18

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

TerminatedNCT01675154

University of Texas Southwestern Medical CenterType 1 Hyperlipoproteinemia

Start: 2015-11-30End: 2020-06-30Updated: 2021-08-19